MABBI – Research conducted by Rizal Irfandi, Santi, Indah Raya, Ahyar Ahmad, Ahmad Fudholi, Dewi Ratih Tirto Sari, and Prihantono from Puangrimaggalatung University entitled Study of new Zn(II)Prolinedithiocarbamate as a potential agent for breast cancer: Characterization and molecular docking
This study characterized the synthetic Zn(II)Prolinedithiocarbamate and determined its anti-cancer activity in vitro and in silico. Zn(II)Prolineditiocarbamate complex was synthesized, characterized, and determined by melting point, conductivity value, UV–Vis spectroscopy, FT-IR and XRD. Computational NMR spectrum analysis has been carried out. Zn(II)Prolinedithiocarbamate complex’s binding to DNA was studied using an in vitro molecular docking anti-cancer activity assay. Molecular docking results showed the interaction of Zn(II)Prolinedithiocarbamate complex with DNA from MCF-7 strain cells. Cytotoxicity of Zn(II)Prolinethiocarbamate against the MCF-7 cell line showed changes in cancer cell morphology at an IC50 value of 360.10 g/mL. Zn(II)Prolinedithiocarbamate complex compounds can be a breakthrough in developing chemotherapy drugs that are potential and effective against the MCF-7 cell line. (Tri/MABBI)
Read more:https://www.sciencedirect.com/science/article/pii/S0022286021022213
Leave a Reply